Evidence map›Paper›PMID 38531958›Full record

ArticleScientific reports2024

Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.

Leander van Eekelen, Joey Spronck, Monika Looijen-Salamon, Shoko Vos, Enrico Munari, Ilaria Girolami, Albino Eccher, Balazs Acs, Ceren Boyaci, Gabriel Silva de Souza and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Leander van EekelenDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands. leander.vaneekelen@radboudumc.nl.
Joey SpronckDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Monika Looijen-SalamonDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Shoko VosDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Enrico MunariPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Ilaria GirolamiDepartment of Pathology, Provincial Hospital of Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.
Albino EccherDepartment of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.
Balazs AcsDepartment of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
Ceren BoyaciDepartment of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
Gabriel Silva de SouzaDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Muradije Demirel-AndishmandDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Luca Dulce MeestersDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Daan ZegersDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Lieke van der WoudeDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Willemijn TheelenDepartment of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Michel van den HeuvelRespiratory Diseases Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Katrien GrünbergDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Bram van GinnekenDepartment of Radiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Jeroen van der LaakDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Francesco CiompiDepartment of Pathology, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Radboud University Medical Center · NLRadboud University Nijmegen · NLKarolinska University Hospital · SEOspedale di Bolzano · ITThe Netherlands Cancer Institute · NLUniversity of Brescia · IT

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 18388
6 · The paper itself

Abstract

Programmed death-ligand 1 (PD-L1) expression is currently used in the clinic to assess eligibility for immune-checkpoint inhibitors via the tumor proportion score (TPS), but its efficacy is limited by high interobserver variability. Multiple papers have presented systems for the automatic quantification of TPS, but none report on the task of determining cell-level PD-L1 expression and often reserve their evaluation to a single PD-L1 monoclonal antibody or clinical center. In this paper, we report on a deep learning algorithm for detecting PD-L1 negative and positive tumor cells at a cellular level and evaluate it on a cell-level reference standard established by six readers on a multi-centric, multi PD-L1 assay dataset. This reference standard also provides for the first time a benchmark for computer vision algorithms. In addition, in line with other papers, we also evaluate our algorithm at slide-level by measuring the agreement between the algorithm and six pathologists on TPS quantification. We find a moderately low interobserver agreement at cell-level level (mean reader-reader F1 score = 0.68) which our algorithm sits slightly under (mean reader-AI F1 score = 0.55), especially for cases from the clinical center not included in the training set. Despite this, we find good AI-pathologist agreement on quantifying TPS compared to the interobserver agreement (mean reader-reader Cohen's kappa = 0.54, 95% CI 0.26-0.81, mean reader-AI kappa = 0.49, 95% CI 0.27-0.72). In conclusion, our deep learning algorithm demonstrates promise in detecting PD-L1 expression at a cellular level and exhibits favorable agreement with pathologists in quantifying the tumor proportion score (TPS). We publicly release our models for use via the Grand-Challenge platform.

Indexed as

Carcinoma, Non-Small-Cell LungDeep LearningLung NeoplasmsB7-H1 AntigenBiomarkers, TumorHumansImmunohistochemistryPathologistsB7-H1 AntigenBiomarkers, Tumor

Identifiers

PMID38531958
PMCPMC10965947
OpenAlexW4393192862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.